DABRAFENIB , TRAMETINIB clinical trials

(NEOAC) NEO- and Adjuvant Targeted therapy in braf-mutated Anaplastic Cancer of the Thyroid - a prospective, non-randomized, single center, open-label phase II study.

This study looks at new drug treatments before and after surgery for a type of aggressive thyroid cancer. It aims to see if these drugs, dabrafenib and trametinib, can shrink tumours enough to make surgery more successful and improve patients' chances of recovery.